Phillips D H, Hewer A, Grover P L, Poon G K, Carmichael P L
Haddow Laboratories, Sutton, Surrey, UK.
Carcinogenesis. 1996 May;17(5):1149-52. doi: 10.1093/carcin/17.5.1149.
DNA from white blood cells of seven women receiving tamoxifen as adjuvant therapy for breast cancer and of three women who served as healthy controls was analysed for the presence of tamoxifen-DNA adducts using 32P-postlabelling with a limit of detection of 8 adducts/10(10) nucleotides. No postlabelled adducts with the chromatographic properties of known tamoxifen-DNA adducts were detected in any of the samples. It is concluded that at therapeutic levels of exposure there is no significant formation of DNA adducts by tamoxifen or its metabolites in circulating white blood cells.
对7名接受他莫昔芬辅助治疗乳腺癌的女性以及3名作为健康对照的女性的白细胞DNA进行分析，采用³²P后标记法检测他莫昔芬-DNA加合物，检测限为8个加合物/10¹⁰个核苷酸。在任何样本中均未检测到具有已知他莫昔芬-DNA加合物色谱特性的后标记加合物。得出的结论是，在治疗暴露水平下，他莫昔芬及其代谢产物在循环白细胞中不会显著形成DNA加合物。
